<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cuzzoni, E</style></author><author><style face="normal" font="default" size="100%">De Iudicibus, S</style></author><author><style face="normal" font="default" size="100%">Stocco, G</style></author><author><style face="normal" font="default" size="100%">Favretto, D</style></author><author><style face="normal" font="default" size="100%">Pelin, M</style></author><author><style face="normal" font="default" size="100%">Messina, G</style></author><author><style face="normal" font="default" size="100%">Ghio, L</style></author><author><style face="normal" font="default" size="100%">Monti, E</style></author><author><style face="normal" font="default" size="100%">Pasini, A</style></author><author><style face="normal" font="default" size="100%">Montini, G</style></author><author><style face="normal" font="default" size="100%">Decorti, G</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">Nefrokid group</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">In vitro sensitivity to methyl-prednisolone is associated with clinical response in pediatric idiopathic nephrotic syndrome.</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Pharmacol Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Clin. Pharmacol. Ther.</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Sep</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">100</style></volume><pages><style face="normal" font="default" size="100%">268-74</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The aim of this study was to evaluate the in vitro steroid sensitivity as a predictor of clinical response to glucocorticoids in childhood idiopathic nephrotic syndrome (INS). Seventy-four patients (median age 4.33, interquartile range [IQR] 2.82-7.23; 63.5% male) were enrolled in a prospective multicenter study: in vitro steroid inhibition of patients' peripheral blood mononuclear cell proliferation was evaluated by [methyl-(3) H] thymidine incorporation assay at disease onset (T0) and after 4 weeks (T4) of treatment. Steroid dependence was associated with increased in vitro sensitivity at T4 assessed both as drug concentration inducing 50% of inhibition (IC50 ; odds ratio [OR] = 0.48, 95% confidence interval [CI] = 0.24-0.85; P = 0.0094) and maximum inhibition at the highest drug concentration (Imax ; OR = 1.13, 95% CI = 1.02-1.31; P = 0.017). IC50 &gt; 4.4 nM and Imax &lt; 92% at T4 were good predictors for optimal clinical response. These results suggest that this test may be useful for predicting the response to glucocorticoid therapy in pediatric INS.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/27007551?dopt=Abstract</style></custom1></record></records></xml>